390 related articles for article (PubMed ID: 25417708)
1. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.
Stockmann C; Hillyard B; Ampofo K; Spigarelli MG; Sherwin CM
Expert Rev Respir Med; 2015 Feb; 9(1):13-22. PubMed ID: 25417708
[TBL] [Abstract][Full Text] [Related]
2. Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis.
Stockmann C; Sherwin CM; Ampofo K; Spigarelli MG
Ther Adv Respir Dis; 2014 Feb; 8(1):13-21. PubMed ID: 24334337
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
Stass H; Delesen H; Nagelschmitz J; Staab D
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
[TBL] [Abstract][Full Text] [Related]
4. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.
Geller DE; Flume PA; Staab D; Fischer R; Loutit JS; Conrad DJ;
Am J Respir Crit Care Med; 2011 Jun; 183(11):1510-6. PubMed ID: 21471106
[TBL] [Abstract][Full Text] [Related]
5. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis.
Hansen C; Skov M
Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692
[TBL] [Abstract][Full Text] [Related]
6. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
7. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
8. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
Flume PA; VanDevanter DR; Morgan EE; Dudley MN; Loutit JS; Bell SC; Kerem E; Fischer R; Smyth AR; Aaron SD; Conrad D; Geller DE; Elborn JS
J Cyst Fibros; 2016 Jul; 15(4):495-502. PubMed ID: 26852040
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.
Elborn JS; Flume PA; Cohen F; Loutit J; VanDevanter DR
J Cyst Fibros; 2016 Sep; 15(5):634-40. PubMed ID: 26935334
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
Ballmann M; Smyth A; Geller DE
Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
[TBL] [Abstract][Full Text] [Related]
11. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
12. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986
[TBL] [Abstract][Full Text] [Related]
13. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972
[TBL] [Abstract][Full Text] [Related]
14. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
[TBL] [Abstract][Full Text] [Related]
15. The problems of antibiotic resistance in cystic fibrosis and solutions.
López-Causapé C; Rojo-Molinero E; Macià MD; Oliver A
Expert Rev Respir Med; 2015 Feb; 9(1):73-88. PubMed ID: 25541089
[TBL] [Abstract][Full Text] [Related]
16. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Smith S; Waters V; Jahnke N; Ratjen F
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
[TBL] [Abstract][Full Text] [Related]
17. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
Taccetti G; Campana S; Festini F; Mascherini M; Döring G
Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
[TBL] [Abstract][Full Text] [Related]
18. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
Assael BM
Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
[TBL] [Abstract][Full Text] [Related]
19. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.
Connett GJ; Pike KC; Legg JP; Cathie K; Dewar A; Foote K; Harris A; Faust SN
Ther Adv Respir Dis; 2015 Dec; 9(6):272-80. PubMed ID: 26341118
[TBL] [Abstract][Full Text] [Related]
20. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
